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Abstract
Background: Many cancers are known to be associated with paraneoplastic syndromes. These
syndromes are usually treated by chemotherapy with or without immunosupression but they often
respond poorly. There are no published reviews on response to endocrine treatment.
Case presentation: We report a case of a patient presenting with papillitis, myositis and sensory
peripheral neuropathy 18 months before a diagnosis of metastatic oestrogen receptor positive
breast cancer was confirmed. The patient was treated with anastrozole which led not only to a
decrease of her tumour burden but also to an improvement in her biochemical markers and
amelioration of her clinical symptoms.
Conclusion:  T h i s  c a s e  i s  a n  e x a m p l e  o f  b r e a s t  cancer presenting with paraneoplastic
manifestations. It took several months to establish the cause of symptoms in this patient thus
illustrating the need for physicians to maintain a high index of suspicion for paraneoplastic
syndromes in women presenting with unusual neurological symptoms with no obvious cause.
It is a unique case as it illustrates how treatment with an aromatase inhibitor leading to cancer 
regression can result in an improvement in the paraneoplastic symptoms.
Background
Many cancers are known to be associated with paraneo-
plastic syndromes. These syndromes are often poorly
responsive to treatment. We herein report a 54 year old
woman confirmed to have a paraneoplastic manifestation
of breast cancer that responded to therapy with an aro-
matase inhibitor.
Case presentation
A 54 year old woman (with a background of hypertension
and asthma) presented to the ophthalmology department
with an abrupt onset of left visual field loss. This was char-
acterised as an inferior quadrantinopia. She also had an
enlarged blind spot on the right and at this time fundos-
copy revealed a markedly swollen right optic disc sugges-
tive of papillitis. This visual defect persisted for several
weeks but eventually disappeared. She was left with the
right optic nerve lesion.
Eight months later she was referred to the stroke services.
She had developed a balance disturbance. For four
months she had also been experiencing progressive
numbness of her feet along with weakness of her legs,
worse on the right. She had noted poorer motor control of
her right hand. She was becoming increasingly fatigued
and breathless on exertion. Examination revealed obesity.
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She had no new cranial nerve signs. Peripheral nervous
system examination showed absent ankle jerks and pin-
prick sensation was impaired on the feet.
Given her non-specific presentation, the diagnosis was
uncertain. Routine biochemistry, pituitary function tests,
CT brain and MRI pituitary fossa were all normal. She was
noted to have an elevated IgG at 21.6 and a raised SMA
titre (IgG class >800). Type 2 diabetes mellitus was con-
firmed with an oral glucose tolerance test.
On routine review three months later her mobility had
continued to decline and the impaired pin-prick sensation
was now to the level of the upper tibiae. She had devel-
oped palpable lymph nodes in her supraclavicular fossa.
Smooth muscle antibody (SMA) remained elevated; creat-
inine kinase (CK) was checked and was elevated at 360.
IgG remained greater than 20.
A CT scan was therefore performed demonstrating cervical
and axillary lymphadenopathy. There was no visceral dis-
ease. Biopsy of the axillary lymph node confirmed the
diagnosis of an oestrogen receptor (ER) positive invasive
carcinoma of mammary type. Mammography and ultra-
sound of the breasts were unremarkable.
She was therefore commenced on anastrozole. On review
after 3 months of treatment she reported improved walk-
ing balance and improved numbness in her legs but no
improvement in her right hand. Repeat CT confirmed
reduction in the size of the lymph nodes. CK was still ele-
vated at 453 but IgG was improved at 18.1. At 8 months
of treatment with anastrozole, the CK has started to fall
(figure 1). Symptomatically her balance has improved.
Her walking is still impaired but she has had no further
deterioration.
Discussion
Paraneoplastic syndromes are caused by cancer but are
not due directly to local infiltration or metastatic spread.
They are thought to be due to either inappropriate secre-
tion of hormones or the production of anti-tumoral anti-
bodies that cross react with normal tissue antigens [1].
The diagnosis is mainly based on clinical features and
excluding non-malignant causes. Laboratory based tests
are useful if there is no obvious tumour. Many but not all
patients with paraneoplastic syndromes have identifiable
antibodies in their serum. Paraneoplastic antibody panels
detect antibodies in patients' serum that react with both
the nervous system and the underlying cancer. Each of
these antibodies is associated with a narrow spectrum of
clinical syndromes and a restricted subgroup of cancers
[2].
Paraneoplastic syndromes can affect most organs and tis-
sues with cancer cachexia and hypercalcaemia being com-
mon examples [1]. This patient had a neurological
syndrome experiencing papillitis, myositis and sensory
peripheral neuropathy. There are many other neurological
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manifestations of paraneoplastic syndromes including
motor neuropathy, autonomic neuropathy, limbic
encephalitis, cerebellar degeneration and Lambert-Eaton
myaesthenic syndrome [2].
Many of the paraneoplastic conditions are poorly respon-
sive to treatment. A previous review of 31 reported cases
of paraneoplastic neurological syndromes due to breast
cancer reported only 29% of patients responded to chem-
otherapy with an improvement in neurological deficits
[3]. Often these syndromes present a problem as there is
no apparent tumour and therefore unknown receptors.
For this reason chemotherapy with or without immuno-
supression is more commonly the treatment of choice.
There are no published reviews on response to endocrine
treatment however this case illustrates a patient respond-
ing to an aromatase inhibitor. This suggests that endo-
crine therapy may be an appropriate treatment for the
paraneoplastic manifestations of breast cancer in patients
with hormone responsive tumours.
This lady's quality of life improved substantially once the
cause for her symptoms was diagnosed and adequately
treated. Unfortunately it took several months to establish
the diagnosis thus illustrating the need for physicians to
maintain a high index of suspicion for paraneoplastic syn-
dromes in women presenting with unusual neurological
symptoms with no obvious cause.
In breast cancer patients it has been reported that the
severity of dermatomyositis follows the clinical course of
the malignancy [4]. The severity of this patient's symp-
toms and the level of her serum CK appeared to correlate
with her tumour load. The improvement in the biochem-
ical markers (of the paraneoplastic manifestations) lagged
behind the patient's clinical and radiological improve-
ment. This differs from serum tumour marker changes
which tend to pre-date clinical and radiological response
or progression. However, both of these markers could be
potentially useful during monitoring of patients.
Conclusion
Our case has shown that ER positive breast cancer may
present with paraneoplastic manifestations including
papillitis, neuropathy and myositis. Endocrine treatment
not only led to tumour regression but also to an improve-
ment in the biochemical markers (CK and IgG) and clini-
cal symptoms. The severity of her symptoms and level of
her biochemical markers correlated with her tumour load.
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